Additional Information

Description

Anastrozole 0.25 mg is a nonsteroidal aromatase inhibitor used as adjuvant treatment in postmenopausal women with hormone receptor-positive early-stage breast cancer. By inhibiting the aromatase enzyme, it reduces systemic estrogen levels, thereby limiting the growth of estrogen-dependent tumors. It is administered orally, typically at a dose of 0.25 mg once daily.

Anastrozole may cause decreased bone mineral density due to reduced estrogen, increasing the risk of osteoporosis. Patients undergoing long-term therapy should be regularly monitored for signs of bone loss. Dual-energy X-ray absorptiometry (DEXA) scans are recommended to assess bone mineral density. Supplementation with calcium and vitamin D may be considered as supportive therapy.

Although no significant drug interactions have been reported, hypersensitivity to anastrozole remains a contraindication. Adverse effects may include bone pain and fatigue. The drug has also been associated with an increased risk of fractures, reinforcing the need for routine bone health evaluations during treatment.